Recruitment | Acumen Pharmaceuticals

2023 CTAD Poster

May 31, 2024/in 2023 CTAD, INTERCEPT-AD, Poster, Recruitment, tw, TwentyTwentyThree /by Robyn Moxon

2023 CTAD Poster:

Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.

2023 AAIC Presentation

May 31, 2023/in 2023 2023, AAIC, INTERCEPT-AD, Presentation, Recruitment, Topline, TwentyTwentyThree /by Robyn Moxon

2023 AAIC Presentation:

Topline results of INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.